• Human iPSC-Derived Intestinal Organoids for PK Studies

  2026-05-03

  This study introduces a rapid and reliable protocol for generating human intestinal organoids from induced pluripotent stem cells (hiPSCs), overcoming prior limitations of time-consuming, multi-step differentiation. The platform provides a physiologically relevant in vitro system for pharmacokinetic assessment of orally administered drugs, offering improved modeling over animal or cancer cell line alternatives.

• Gramine Induces Ferroptosis in TNBC via CUL3–MTDH Ubiquitina

  2026-05-02

  This study uncovers a novel mechanism by which the natural alkaloid gramine suppresses triple-negative breast cancer (TNBC) by inducing ferroptosis through CUL3-mediated ubiquitination of MTDH. These findings highlight a promising molecular target for therapeutic intervention in TNBC and provide a foundation for future research on ferroptosis-based cancer therapies.

• SCUBE3 Antibody Targeting: Suppressing Cancer via Oncogenic

  2026-05-02

  This study identifies secreted SCUBE3 as a critical driver of tumor growth, therapy resistance, and immune evasion in cancer models. Using a first-in-class neutralizing antibody, the research demonstrates robust suppression of cancer progression by simultaneously inhibiting oncogenic signaling and reversing immunosuppression, highlighting a promising new strategy for pan-cancer therapeutic development.

• Macrophage-Amphiregulin Axis Drives Fibrosis in S. aureus Os

  2026-05-01

  This study reveals that macrophage-derived amphiregulin (AREG) initiates myofibroblast transition in adipogenic precursors near Staphylococcus aureus abscesses in bone marrow, driving pathological fibrosis and impairing vascular perfusion. Targeting the AREG/EGFR/mTOR signaling axis enhances antibiotic efficacy, shedding light on new intervention strategies for persistent bone infections.

• 2'3'-cGAMP (sodium salt): Optimizing STING Pathway Assays

  2026-04-30

  2'3'-cGAMP (sodium salt) empowers researchers with unmatched specificity and potency for dissecting the cGAS-STING pathway, making it essential for advanced immunology and antiviral workflows. APExBIO’s validated reagent streamlines assay reproducibility and enables precise modulation of type I interferon induction.

• Novel Allosteric PDK4 Inhibitors for Metabolic Disease Thera

  2026-04-30

  This article analyzes the discovery of highly selective allosteric inhibitors of pyruvate dehydrogenase kinase 4 (PDK4), focusing on compound 8c, which demonstrates nanomolar potency, metabolic stability, and in vivo efficacy for metabolic, allergic, and tumor models. The findings provide a robust foundation for targeted modulation of mitochondrial energy metabolism in research and potential therapy.

• Otilonium Bromide: Antimuscarinic Agent for Precision Cell A

  2026-04-29

  Otilonium Bromide from APExBIO empowers smooth muscle and neuroscience researchers with high-purity, flexible formats, and robust receptor selectivity. This article delivers actionable workflows, troubleshooting strategies, and protocol optimizations for cholinergic signaling assays, distinguishing Otilonium Bromide as a cornerstone in advanced biomedical research.

• Cyclic Pifithrin-α Hydrobromide: Optimizing p53 Inhibition W

  2026-04-29

  Cyclic Pifithrin-α hydrobromide empowers researchers to precisely modulate p53-dependent pathways for advanced studies in apoptosis inhibition, DNA damage response, and side effect mitigation during cancer therapy. This guide translates recent neuroinflammatory research and in vivo protection strategies into robust, reproducible protocols for both oncology and neuroscience laboratories.

• Imatinib Hydrochloride: Optimized Workflows for Kinase Resea

  2026-04-28

  Imatinib hydrochloride (STI571 hydrochloride) is a benchmark tyrosine kinase inhibitor for cancer research, enabling robust analysis of oncogenic signaling. This guide delivers actionable protocols, troubleshooting insights, and leverages breakthrough findings in kinase-phosphatase dynamics—maximizing reproducibility and translational power in CML and GIST models.

• Cy5 NHS ester(Et): Technical Guidance for Protein Labeling

  2026-04-28

  Cy5 NHS ester(Et) is a water-soluble fluorescent dye engineered for fast, stable labeling of primary amine groups in biomolecules, supporting workflows such as immunofluorescence staining, flow cytometry, and fluorescence microscopy. It is not suitable for ethanol-based protocols or long-term storage of working solutions. Researchers benefit from its high purity and robust amine-reactivity, but must adhere to handling and dissolution best practices for optimal results.

• circHIF1A/miR-486-5p/GRHL2 Axis Drives M2 Polarization in LU

  2026-04-27

  This study delineates the role of the circHIF1A/miR-486-5p/GRHL2 regulatory axis in promoting macrophage M2 polarization and lung adenocarcinoma (LUAD) progression. By elucidating the ceRNA network's impact on tumor microenvironment remodeling, it identifies both a prognostic biomarker and a potential therapeutic target for LUAD.

• Ceftolozane/Tazobactam: Addressing Gram-Negative Resistance

  2026-04-27

  This article analyzes the innovation and clinical relevance of ceftolozane/tazobactam, a novel cephalosporin/β-lactamase inhibitor designed to treat complicated infections by multidrug-resistant gram-negative pathogens. The study’s pharmacokinetic, pharmacodynamic, and safety findings establish an evidence base for improved therapeutic strategies in settings of increasing antimicrobial resistance.

• ROS-Responsive Nanoparticles Induce Cuproptosis for Cancer I

  2026-04-26

  This study introduces ROS-sensitive polymeric nanoparticles co-encapsulating elesclomol and copper to induce cuproptosis in bladder cancer cells and enhance antitumor immunity, especially when combined with αPD-L1 checkpoint blockade. The findings demonstrate a pioneering strategy for overcoming immune resistance and improving cancer therapy outcomes.

• Broad-Spectrum Bivalent mRNA Vaccine Shows Preclinical Effic

  2026-04-25

  This study introduces and evaluates RQ3025, a bivalent mRNA vaccine designed to target a broad range of SARS-CoV-2 variants. Preclinical evidence demonstrates its ability to induce potent neutralizing antibodies and a Th1-biased immune response, supporting its relevance for future vaccine development.

• Coronavirus Macrodomains Counteract PARP-Mediated Antiviral

  2026-04-24

  This study reveals that the coronavirus macrodomain is essential for evading host poly(ADP-ribose) polymerase (PARP)-mediated inhibition of viral replication and for modulating interferon responses. These insights deepen our understanding of virus-host interactions and highlight the relevance of PARP inhibition tools for dissecting innate immune mechanisms.

443 records 19/30 page Previous Next First page 上5页 1617181920 下5页 Last page